DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
DarioHealth Corp.NASDAQ: DRIO
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $6.06M (cash outflow) fell 9.7% year over year, ahead of the -21.1% change in trailing-twelve-month free cash flow. Sequentially, it rose 2.4% from the prior quarter. Over 3 fiscal years it compounded at -18.6% a year.
Context
- Free cash flow amounted to 116.7% of revenue in FY2025, down 26.5 pp from a year earlier.
- Free cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -9.7% holds above the trailing-twelve-month pace of -21.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (26.08M) USD
- Year-over-year change
- +32.6%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (26.08M) | +32.6% |
| FY2024 | 2024-12-31 | (38.7M) | -25.0% |
| FY2023 | 2023-12-31 | (30.96M) | +36.1% |
| FY2022 | 2022-12-31 | (48.42M) | +4.4% |
| FY2021 | 2021-12-31 | (50.67M) | — |
Free Cash Flow vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 free cash flow of $25.44M is the 7th largest of the 11 companies compared; the peer median is $59.65M.
- Its year-over-year change of -21.1% is the 6th highest of 11, against a peer median of +1.9%.
- Free cash flow amounts to 120.0% of revenue for DRIO, versus a peer median of 52.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $236.4M | +171.9% | -19.0% | 269.2% | |
| LTM Mar 2026 | $152.29M | +32.3% | +29.3% | 307.1% | |
| LTM Mar 2026 | $116.21M | -36.5% | -25.9% | 72.6% | |
| LTM Mar 2026 | $113.17M | +258.0% | — | 35.3% | |
| LTM Mar 2026 | $98.51M | +28.3% | -1.2% | 5365.2% | |
| LTM Mar 2026 | $38.87M | +143.1% | — | 4.1% | |
| LTM Mar 2026 | $25.44M | -21.1% | -18.6% | 120.0% | |
| LTM Mar 2026 | $20.8M | -41.9% | -55.0% | 2.5% | |
| LTM Mar 2026 | $7.5M | -93.4% | -15.6% | 1.0% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $6.74M | -423.9% | — | 69.1% |
| LTM Mar 2026 | $3.63M | -24.4% | -66.7% | 0.4% | |
| Peer median (excluding DRIO) | $59.65M | +1.9% | -19.0% | 52.2% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 2.83M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.97M | 16.98M | 19.7M | 15.8M | 9.37M |
| Change in Working Capital | (2.57M) | (10.9M) | 4.07M | (2.47M) | 2.21M |
| Accounts Receivables | (367K) | (5.11M) | 2.84M | 1.6M | 2.64M |
| Inventory | (2.23M) | (1.73M) | 2.89M | 308K | 437K |
| Accounts Payables | 1.08M | (2.79M) | (1.19M) | (496K) | (122K) |
| Other Working Capital | (1.06M) | (1.28M) | (464K) | (3.88M) | (752K) |
| Other Non-Cash Items | (503K) | 3.56M | 288K | (16.57M) | 1.37M |
| Operating Cash Flow | (50.41M) | (47.85M) | (30.38M) | (38.56M) | (25.94M) |
| Capital Expenditures | (261K) | (573K) | (584K) | (138K) | (142K) |
| Acquisitions (Net) | (7.47M) | 0 | 0 | (8.8M) | 0 |
| Purchases of Investments | 0 | 0 | (5M) | 0 | (4.2M) |
| Sales of Investments | 0 | 0 | 5.03M | 0 | 0 |
| Other Investing Activities | (400K) | (131K) | 0 | 0 | 0 |
| Investing Cash Flow | (8.13M) | (573K) | (547K) | (8.93M) | (4.34M) |
| Debt Repayment | 0 | 23.79M | 1.77M | 0 | 185K |
| Common Stock Issued | 64.88M | 38.29M | 1.61M | 0 | 24.13M |
| Common Stock Repurchased | 0 | (134K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 889K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 65.77M | 61.94M | 18.25M | 38.53M | 24.31M |
| Effect of Forex Changes | 0 | 0 | 0 | (68K) | 9K |
| Net Change in Cash | 7.22M | 13.52M | (12.67M) | (9.03M) | (5.96M) |
| Free Cash Flow | (50.67M) | (48.42M) | (30.96M) | (38.7M) | (26.08M) |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.